

30 October 2025

ASX Announcement

Firebrick Announces New Product: Nasodine Throat Spray

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that it has commenced manufacture of Nasodine® Throat Spray for export in November 2025, which will be the first new product in the Nasodine range since Nasodine Nasal Spray, which was launched in Singapore in 2024.

Nasodine Throat Spray is a 1.0% povidone-iodine formulation for treatment of sore throats in a convenient throat spray form, as distinct from the throat gargle that is already available in many markets. The low volume means there is no need to expectorate (spit out) unused solution, avoiding the potential staining and inconvenience of the gargle format. Details about the Throat Spray can be found in the section of this release titled 'About Nasodine Throat Spray'.

The Company has received a permit from the TGA (Therapeutic Goods Administration) (<https://www.tga.gov.au/resources/artg/517465>) that allows export of the new Throat Spray product from Australia, but not local sale in Australia. .

Firebrick has already placed on order for production of an initial batch of the Throat Spray with its Australian manufacturing partner, Probiotec. Product is expected to be released and available for export during November 2025.

The first market where the Throat Spray will be launched is Singapore, where like Nasodine Nasal Spray, it can be sold as an antiseptic and does not require local regulatory approval. The Company's licensing partner, Innorini Life Sciences (**Innorini**), expects marketing of the Throat Spray to start in December, focused on Singapore hospitals and doctors (HCPs). They expect the product to be available in the retail channel around mid-2026.

Nasodine Throat Spray is the first new Nasodine-brand product after Nasodine Nasal Spray and heralds a range of Nasodine-brand products in the future, which will also follow in the footsteps of the nasal spray.

About Nasodine Throat Spray

Nasodine® Throat Spray is a 1% povidone-iodine antiseptic sore throat treatment in a compact, convenient and ready-to-use package with a pleasant tasting formulation. Each bottle contains 25mL of solution.

The incorporated nozzle provides precise targeting of a low volume of solution directly to the affected area. The low volume means there is no need to expectorate (spit out) unused solution, avoiding the potential staining and inconvenience of the gargle format. The throat spray format for povidone-iodine is already available in Singapore and some other markets under the “Betadine” brand but is not currently available in Australia.

In Singapore, from December 2025, the product will be made available online through nasodine-sg.com.

This announcement was authorised for release by the Board of Firebrick Pharma.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. During 2024, Firebrick introduced Nasodine in the United States and Singapore, and more recently announced launches in Fiji and Brunei.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com

